Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,766 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,441 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,353)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01011894 | Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age | completed | Phase 2 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00863434 | Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT00997243 | Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes | terminated | Phase 2 | 7 | Alison WalkerOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01191749 | Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL) | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01133743 | Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 31 | University Health Network, TorontoOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT02371577 | Evaluation of the Immune Restoration Potential Of Lenalidomide(Revlimid) | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT02963038 | CAR T Cells for Refractory B Cell Malignancy | unknown | Phase 1 / Phase 2 | 10 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01435343 | Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia | completed | Phase 1 / Phase 2 | 55 | PETHEMA FoundationOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02520102 | Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia | withdrawn | Phase 2 | 0 | SanofiINDUSTRY | 0 | Apr 20, 2017 | clinicaltrials |
| NCT01414205 | A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE) | completed | Phase 2 | 80 | Genentech, Inc.INDUSTRY | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01868893 | An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia | completed | Phase 2 | 20 | Genentech, Inc.INDUSTRY | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01173679 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | terminated | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Apr 14, 2017 | clinicaltrials |
| NCT01363297 | Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia | completed | Phase 2 | 72 | PfizerINDUSTRY | 1 | Apr 13, 2017 | clinicaltrials |
| NCT00596336 | Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients(CLLIFVAC) | terminated | Phase 2 | 24 | The Royal Bournemouth HospitalOTHER | 1 | Apr 12, 2017 | clinicaltrials |
| NCT00923910 | Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood | completed | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Apr 12, 2017 | clinicaltrials |
| NCT02973191 | A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia(ORBIT) | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 7 | Apr 10, 2017 | clinicaltrials |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | terminated | Phase 2 | 36 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00636909 | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders(MINI HEME) | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 0 | Apr 6, 2017 | clinicaltrials |
| NCT02227108 | Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma | terminated | Phase 2 | 37 | MedImmune LLCINDUSTRY | 8 | Apr 6, 2017 | clinicaltrials |
| NCT00091559 | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) | completed | Phase 2 | 74 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 5, 2017 | clinicaltrials |
| NCT00360776 | Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2017 | clinicaltrials |
| NCT01396070 | Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level | completed | Phase 2 | 36 | Youn KimOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT00906945 | Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 39 | Washington University School of MedicineOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01465386 | Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission | terminated | Phase 2 | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT03080922 | High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 10 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | terminated | Phase 2 | 14 | University of ArizonaOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT01607645 | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS | terminated | Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00973752 | Treatment of Older Adults With Acute Lymphoblastic Leukemia | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01118013 | Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant | terminated | Phase 2 | 6 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 24, 2017 | clinicaltrials |
| NCT02685670 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma(MatchCART) | unknown | Phase 1 / Phase 2 | 20 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT00469859 | Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 14 | Children's Oncology GroupNETWORK | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01357655 | Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) | terminated | Phase 2 | 70 | Bristol-Myers SquibbINDUSTRY | 8 | Mar 14, 2017 | clinicaltrials |
| NCT01944943 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia(VISMOLY) | terminated | Phase 2 | 31 | The Lymphoma Academic Research OrganisationOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT02912754 | Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients | unknown | Phase 1 / Phase 2 | 36 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 13, 2017 | clinicaltrials |
| NCT00587054 | Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders | completed | Phase 2 | 129 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00321932 | Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 61 | University of MinnesotaOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01181271 | Tandem Auto-Allo Transplant for Lymphoma | completed | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT00143845 | Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant | completed | Phase 2 | 54 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 8, 2017 | clinicaltrials |
| NCT00179790 | Reduced Intensity Transplant Using Extracorporeal Photopheresis | completed | Phase 1 / Phase 2 | 22 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00264160 | Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy | completed | Phase 2 / Phase 3 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00307086 | Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT01209286 | Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 36 | Amgen Research (Munich) GmbHINDUSTRY | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00171912 | Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes | completed | Phase 2 | 38 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00880269 | Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 12 | Feb 23, 2017 | clinicaltrials |
| NCT01621477 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | terminated | Phase 2 | 34 | St. Jude Children's Research HospitalOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT01843179 | Sulindac for Patients With AML | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
Data updated 24 days agoSource updated May 18, 2017source: clinicaltrials